Endocrinology
News
EMPEROR-Preserved: Empagliflozin’s HFpEF efficacy catalyzes a heart failure redefinition
Cardiologists have long defined heart failure as involving reduced or preserved ejection fraction. Results from big empagliflozin trials say...
News
PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF
News
At 18 months, much still unknown about diabetes and COVID-19
News
EMPEROR-Preserved spouts torrent of reports on empagliflozin treatment of HFpEF
The primary report from EMPEROR-Preserved on using empagliflozin to treat patients with HFpEF arrived with four other analyses published in its...
News
Dapagliflozin in HFrEF may cut arrhythmias, sudden death: DAPA-HF
Response to the positive findings was tempered, however, by the post hoc nature of the analysis, choice of primary outcome, and inconsistencies...
News
EMPEROR-Preserved: Empagliflozin scores HFpEF breakthrough
Empagliflozin is the first treatment to produce an unequivocal, hard-endpoint benefit in patients with heart failure with preserved ejection...
News
U.S. kidney transplants grow in number and success
Data from 1996 to 2019 show more U.S. kidney transplants recently than ever before, and steady improvements in graft and patient survival.
News
SGLT2 inhibitor use rising in patients with DKD
News
Empagliflozin gets HFrEF approval from FDA
The SGLT2 inhibitor empagliflozin (Jardiance) becomes the second agent from this class to get a heart failure indication regardless of diabetes...
News
Patients with diabetes more likely to be hospitalized, especially with foot infection